Oral feeding of Bifidobacterium bifidum (BGN4) prevents CD4(+) CD45RB(high) T cell-mediated inflammatory bowel disease by inhibition of disordered T cell activation.
Probiotics have been considered as preventive agents for the control of inflammatory bowel disease (IBD). In this study, we assessed the immunomodulatory effect of Bifidobacterium bifidum BGN4 on the control of IBD using the CD4(+) CD45RB(high) T cell transfer disease model. The mice were fed for 4 weeks with either a conventional diet containing only skim milk or a diet containing skim milk with 0.3% (w/w) BGN4. The BGN4-fed mice showed normal weight growth, fewer clinical symptoms such as thickened wall and inflammatory cell infiltration, and lower levels of CD4(+) T lymphocyte infiltration and inflammatory cytokine productions than the skim milk-fed mice with IBD in the large intestine. Suppression of these cytokine productions, particularly IFN-gamma and MCP-1, through BGN4 treatment was also observed in the in vitro co-culture between intestinal epithelial cells and T cells. These findings suggested that a BGN4 supplemented diet could be helpful for the control of aberrant immune responses in the intestinal tissue.